eFFECTOR Translates $38.6m Into Five Cancer Clinical Trials
Executive Summary
The firm's $38.6m in Series C cash will fund additional clinical trials for lead translation regulator eFT508, support the first human trial for eFT226 and advance a third program into preclinical studies.